MedPath

Cabergoline

CABERGOLINE TABLETS, USPRx only

Approved
Approval ID

bc44d11b-b3f0-4e3d-9da3-4f8852d11734

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jul 27, 2023

Manufacturers
FDA

Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.

DUNS: 780779901

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Cabergoline

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code23155-823
Application NumberANDA076310
Product Classification
M
Marketing Category
C73584
G
Generic Name
Cabergoline
Product Specifications
Route of AdministrationORAL
Effective DateJune 17, 2022
FDA Product Classification

INGREDIENTS (5)

CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QP
Classification: IACT
CABERGOLINEActive
Quantity: 0.5 mg in 1 1
Code: LL60K9J05T
Classification: ACTIB
CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Cabergoline - FDA Drug Approval Details